Soliton (NSDQ:SOLY) announced today that it entered into a distribution and sales agreement with Aesthetic Solutions.
The agreement will see Aesthetic Solutions distribute Soliton’s rapid acoustic pulse (RAP) device and advanced design cartridges during a U.S. commercial launch targeted for the first half of 2021.
Get the full story at our sister site, Medical Design & Outsourcing.
Soliton (NSDQ:SOLY) announced that it intends to offer an undisclosed amount of shares of its common stock in an underwritten public offering.
The Houston-based medical device company also intends to grant underwriters a 30-day option to purchase up to an additional 15% of the number of shares offered.
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the proposed offering, according to a news release.
Soliton develops an FDA-cleared device that uses rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos. It is engaged in bringing the Rapid Acoustic Pulse device to the market and completed a clinical study using the system to improve the appearance of cellulite.